Investment Rating - The report assigns a "Buy" rating for the company, indicating an expected relative price increase of over 20% in the next six months [15]. Core Insights - The company is enhancing its universal CAR-T product portfolio, with the in vivo CAR-T expected to initiate clinical trials in 2026. The proprietary platforms, THANK-uCAR® and THANK-u Plus®TM, are being utilized to develop differentiated universal CAR-T cell products [2][3]. - The company reported a revenue of 1.3 billion yuan in 2025, with a net loss of 1 billion yuan, a significant reduction from the previous year's loss of 8 billion yuan. As of December 31, 2025, cash and cash equivalents stood at 1.12 billion yuan [8]. - The company has received 218 orders for its product, Sikeizai®, from East China Pharmaceutical in 2025 and has been included in the "Commercial Health Insurance Innovative Drug Directory" [8]. Financial Projections - Revenue projections for the company are as follows: 2.6 billion yuan in 2026, 4.9 billion yuan in 2027, and 8 billion yuan in 2028, driven by the commercialization of CT053 and CT041 [10][11]. - The company anticipates a significant increase in net profit, projecting a profit of 63.26 million yuan in 2027 and 249.58 million yuan in 2028, following a net loss of 97.86 million yuan in 2025 [3][11]. - Earnings per share (EPS) are expected to improve from -0.17 yuan in 2025 to 0.43 yuan in 2028, reflecting the anticipated growth in profitability [3][11]. Product Development - The company is advancing multiple universal CAR-T products targeting various antigens, including CT0596 (BCMA) and CT1190B (CD19/CD20), with initial data expected to be presented at the ASH conference in December 2025 [2]. - The in vivo CAR-T candidate, KJ-C2529, targeting CD19/CD20 for B-cell lymphoma, is set to begin clinical trials in 2026 [2].

Core Insights - The article discusses recent collaborations and acquisitions among major pharmaceutical companies in the field of in vivo CAR-T cell therapy, highlighting a preference for lentiviral vector technology over LNP-RNA strategies [2][10]. Group 1: Collaborations and Acquisitions - Astellas' subsidiary Xyphos Biosciences partnered with Kelonia Therapeutics in February 2024 to develop in vivo CAR-T cell therapies, with a potential total deal value exceeding $875 million [2][11]. - Novartis entered a collaboration with Vyriad in November 2024 to discover and develop in vivo CAR-T cell therapies, utilizing Vyriad's lentiviral vector platform [4][14]. - Johnson & Johnson formed a strategic partnership with Kelonia in November 2025, marking its first foray into in vivo CAR-T, although specific financial details were not disclosed [5][15]. Group 2: Financial Details of Collaborations - The Astellas-Kelonia agreement includes an initial payment of $40 million for the first project, with an additional $35 million if a second project is pursued, alongside potential milestone payments nearing $800 million [3][12]. - Novartis and Vyriad's collaboration will involve prepayments, milestone payments, and tiered royalties based on net sales, although specific amounts were not disclosed [4][14]. - The financial terms of the Johnson & Johnson-Kelonia partnership remain undisclosed, but it emphasizes the use of Kelonia's iGPS® platform for developing next-generation CAR-T therapies [5][15]. Group 3: Technological Insights - The iGPS® platform developed by Kelonia is a lentiviral vector-based gene delivery system designed to enhance gene transfer efficiency and achieve tissue specificity [2][11]. - Vyriad's lentiviral vector platform modifies the vesicular stomatitis virus (VSV) to target T cells specifically, allowing for effective CAR payload delivery and reprogramming of T cells into CAR-T cells [4][14]. - Kelonia's KLN-1010, developed using the iGPS® platform, has shown promising clinical data, achieving minimal residual disease (MRD) negative responses in patients [5][16]. Group 4: Industry Trends - The article notes a trend among large pharmaceutical companies favoring lentiviral vector technology over LNP-RNA strategies for in vivo CAR-T therapies, reflecting a preference for established delivery methods with commercial success [10][22]. - The Chinese biopharmaceutical sector is also exploring in vivo CAR-T therapies, with companies like Stone Pharmaceutical leading the development of SYS6020, an mRNA-LNP based CAR-T product [7][19].

Group 1 - The core viewpoint of the articles is that the next-generation "in vivo CAR-T" technology is rapidly emerging, potentially addressing the high costs and accessibility issues associated with traditional CAR-T therapies [1][2]. - Traditional CAR-T therapy involves extracting a patient's T cells, modifying them in a lab, and reinfusing them, which is time-consuming and expensive, often exceeding 1 million yuan per treatment [1]. - In vivo CAR-T technology allows for direct modification of T cells within the patient's body using carriers like viruses or lipid nanoparticles, significantly simplifying the process and reducing costs [2]. Group 2 - The cost of in vivo CAR-T therapy is expected to drop to one-tenth of traditional methods, greatly enhancing accessibility for patients [2]. - The treatment process for in vivo CAR-T can yield results in as little as three days with just one or two intravenous injections, compared to the weeks required for traditional CAR-T [2]. - As the technology matures, patients may receive effective and durable cell therapies through simple injections, potentially expanding the range of treatable diseases and lowering overall medical costs [3].

Core Insights - The in vivo CAR-T therapy market is rapidly gaining traction, with significant mergers and acquisitions by major multinational corporations (MNCs) indicating a strategic shift towards this innovative treatment approach [1][2][3] - The advancements in delivery vector technologies are driving the development of in vivo CAR-T therapies, with a focus on improving targeting efficiency and safety [3][4] Group 1: Mergers and Acquisitions - AstraZeneca acquired EsoBiotec for $1 billion to enhance its in vivo CAR-T therapy portfolio [1][2] - AbbVie announced the acquisition of Capstan Therapeutics for up to $2.1 billion, marking a significant investment in the in vivo CAR-T space [1][2] - Gilead's Kite acquired Interius for $350 million, further expanding its capabilities in cell therapy [1][2] Group 2: Technology Platforms - EsoBiotec's core technology is the engineered nanobody lentivirus (ENaBL) platform, which enhances the specificity of immune cell transfection [4] - Interius utilizes a lentiviral vector to deliver CAR genes, generating CAR-T and CAR-NK cells directly in vivo for targeting B-cell malignancies [3][4] - The mRNA-LNP (lipid nanoparticle) delivery system is gaining attention for its safety profile, allowing for transient CAR expression without permanent genetic modification [7][8] Group 3: Clinical Developments - EsoBiotec's product ESO-T01 has shown promising clinical trial results for multiple myeloma, indicating potential effectiveness in treating relapsed or refractory cases [15][17] - Capstan Therapeutics' candidate CPTX2309 is currently in Phase I trials for autoimmune diseases, showcasing the therapeutic potential of the LNP delivery approach [8][9] Group 4: Industry Trends - The shift from ex vivo to in vivo CAR-T therapies is reshaping the ecosystem, with increased collaboration among technology partners and a focus on delivery efficiency [3][6] - The reliance on upstream CXO (Contract Research Organization) services is significant, with over 65% of CGT (Cell and Gene Therapy) projects involving CXO participation [6][12] - The industry is witnessing a dual approach, with companies like AbbVie investing in both lentiviral and mRNA-LNP technologies to mitigate risks associated with single technology pathways [16][17]